Efficacy of alternative antiandrogen therapy for prostate cancer that relapsed after initial maximum androgen blockade

Korean Journal of Urology

Volumn 52, Issue 7, 2011, Pages 461-465

  Choi, Joon Il ^a   Kim, Yun Beom ^a   Yang, Seung Ok ^a   Lee, Jeong Kee ^a   Jung, Tae Young ^a  

^a Seoul Veterans Hospital   (South Korea)

Author keywords

Androgen antagonists; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

BICALUTAMIDE; CYPROTERONE; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

AGED; ANTIANDROGEN THERAPY; ARTICLE; CANCER PATIENT; CANCER RELAPSE; CASTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; MALE; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RESPONSE TIME; RETROSPECTIVE STUDY; WITHDRAWAL SYNDROME;

EID: 79961243887     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2011.52.7.461     Document Type: Article

References (25)

1. Sharifi N, Dahut WL, Figg WD. Secondary hormonal therapy for prostate cancer: what lies on the horizon? BJU Int 2008;101: 271-4.
2. Seruga B, Tannock IF. The changing face of hormonal therapy for prostate cancer. Ann Oncol 2008;19(Suppl 7):79-85.
3. Sharifi N, Gulley JL, Dahut WL. An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer 2010;17: 305-15.
4. Chodak GW. Maximum androgen blockade: a clinical Update. Rev Urol 2005;7(suppl 5):13-7.
5. Kim SJ, Kim SI. Current treatment strategies for castration-resistant prostate cancer. Korean J Urol 2011;52:157-65.
6. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59:572-83.
7. Van Allen EM, Ryan CJ. Novel secondary hormonal therapy in advanced prostate cancer: an update. Curr Opin Urol 2009;19: 315-21.
8. Han KS, Cho KS, Lee SH, Hong SJ. Estramustine phosphate based chemotherapy for hormone refractory prostate cancer. Korean J Urol 2007;48:684-90.
9. Okegawa T, Nutahara K, Higashihara E. Alternative antiandrogen therapy in patients with castration-resistant prostate cancer: a single-center experience. Int J Urol 2010;17:950-5.
10. Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Belldegrun AS. Secondary hormonal therapy for advanced prostate cancer. J Urol 2006;175:27-34.
11. Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, et al. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol 2008;180:921-7.
12. Nishimura K, Arichi N, Tokugawa S, Yoshioka I, Kishikawa H, Ichikawa Y. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer. Int J Urol 2007;14:264-7.
13. Miyake H, Hara I, Eto H. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. BJU Int 2005;96:791-5.
14. Nakabayashi M, Regan MM, Lifsey D, Kantoff PW, Taplin ME, Sartor O, et al. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer. BJU Int 2005;96: 783-6.
15. Kojima S, Suzuki H, Akakura K, Shimbo M, Ichikawa T, Ito H. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol 2004;171:679-83.
16. Won YJ, Sung J, Jung KW, Kong HJ, Park S, Shin HR, et al. Nationwide cancer incidence in Korea, 2003-2005. Cancer Res Treat 2009;41:122-31.
17. Huggins C, Hodges CV. Studies on prostate cancer, I. the effect of castration, of estrogen and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-7.
18. Huggins C, Scott WW. Bilateral adrenalectomy in prostatic cancer; clinical features and urinary excretion of 17-ketosteroids and estrogen. Ann Surg 1945;122:1031-41.
19. Schmitt B, Wilt TJ, Schellhammer PF, DeMasi V, Sartor O, Crawford ED, et al. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology 2001;57:727-32.
20. Moul JW. Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer. Cancer 2009;115: 3376-8.
21. Park SC, Choi HY, Kim CS, Hong SJ, Kim WJ, Lee SE, et al. Predictive variables of the progression to androgen independent prostate cancer after combined androgen blockade. Korean J Urol 2007;48:408-15.
22. Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 1993;149:607-9.
23. Sartor AO, Tangen CM, Hussain MH, Eisenberger MA, Parab M, Fontana JA, et al. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer 2008;112:2393-400.
24. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.
25. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.